-
1
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study
-
Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study. J Clin Oncol 2008;26:2013-2019.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Díaz-Rubio, E.3
-
2
-
-
0027461840
-
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
-
Scheithauer W, Rosen H, Kornek GV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-755.
-
(1993)
BMJ
, vol.306
, pp. 752-755
-
-
Scheithauer, W.1
Rosen, H.2
Kornek, G.V.3
-
3
-
-
80052251529
-
-
Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century, Washington, DC: The National Academies Press
-
Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Nass SJ, Moses HL, Mendelsohn J, eds. Washington, DC: The National Academies Press, 2010:1-316.
-
(2010)
Reinvigorating the NCI Cooperative Group Program. Nass SJ, Moses HL, Mendelsohn J, Eds
, pp. 1-316
-
-
-
5
-
-
84857106911
-
-
Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health. Transforming the NCI Clinical Trials Enterprise: Overview. Available at, accessed May 5
-
Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health. Transforming the NCI Clinical Trials Enterprise: Overview. Available at http://transformingtrials.cancer.gov/initiatives/overview, accessed May 5, 2011.
-
(2011)
-
-
-
6
-
-
33646228635
-
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
-
Lièvre A, Bachet JB, Le CorreDet al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66: 3992-3995.
-
(2006)
Cancer Res
, vol.66
, pp. 3992-3995
-
-
Lièvre, A.1
Bachet, J.B.2
Le Corre, D.3
-
7
-
-
40849118803
-
Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy [abstract 7LB]
-
Amado RG, Wolf M, Freeman D et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy [abstract 7LB]. Proc Eur Ca Conf 2007;5:8.
-
(2007)
Proc Eur Ca Conf
, vol.5
, pp. 8
-
-
Amado, R.G.1
Wolf, M.2
Freeman, D.3
-
8
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
9
-
-
42049092269
-
Interim results from PACCE: Irinotecan/ bevacizumab panitumumab as first-line treatment for metastatic colorectal cancer [abstract 279]
-
Hecht JR, Mitchell EP, Chidiac T et al. Interim results from PACCE: Irinotecan/ bevacizumab panitumumab as first-line treatment for metastatic colorectal cancer [abstract 279]. Proc GI Symp 2008;5:208.
-
(2008)
Proc GI Symp
, vol.5
, pp. 208
-
-
Hecht, J.R.1
Mitchell, E.P.2
Chidiac, T.3
-
10
-
-
51649120733
-
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract 2]
-
Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract 2]. Proc Am Soc Clin Oncol 2008;26:5s.
-
(2008)
Proc Am Soc Clin Oncol
, vol.5 s
, pp. 26
-
-
van Cutsem, E.1
Lang, I.2
D'haens, G.3
-
11
-
-
51649120733
-
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience [abstract 4000]
-
Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience [abstract 4000]. Proc Am Soc Clin Oncol 2008;26:178s.
-
(2008)
Proc Am Soc Clin Oncol
, vol.178 s
, pp. 26
-
-
Bokemeyer, C.1
Bondarenko, I.2
Hartmann, J.T.3
-
12
-
-
34447264101
-
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial [abstract 4000]
-
Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial [abstract 4000]. Proc Am Soc Clin Oncol 2007;25:164s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.164 s
, pp. 25
-
-
van Cutsem, E.1
Nowacki, M.2
Lang, I.3
-
13
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-1417.
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
van Cutsem, E.1
Köhne, C.H.2
Hitre, E.3
-
14
-
-
36348990562
-
Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study [abstract 4035]
-
Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study [abstract 4035]. Proc Am Soc Clin Oncol 2007;25:172s.
-
(2007)
Proc Am Soc Clin Oncol
, vol.172 s
, pp. 25
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
15
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
-
(2009)
J Clin Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
16
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304: 1812-1820.
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
de Roock, W.1
Jonker, D.J.2
di Nicolantonio, F.3
-
17
-
-
20244377544
-
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate- dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13
-
Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate- dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23:2191-2220.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2191-2220
-
-
Peters, W.P.1
Rosner, G.L.2
Vredenburgh, J.J.3
-
18
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
-
19
-
-
80052229590
-
Association of BRAF mutations and EGFR intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients [abstract 4058]
-
Ruzzo A, Cremolini C, Loupakis F et al. Association of BRAF mutations and EGFR intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients [abstract 4058]. Proc Am Soc Clin Oncol 2009;27:15s.
-
(2009)
Proc Am Soc Clin Oncol
, vol.15 s
, pp. 27
-
-
Ruzzo, A.1
Cremolini, C.2
Loupakis, F.3
-
20
-
-
78649739337
-
Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract 3506]
-
Bokemeyer C, Kohne C, Rougier P et al. Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract 3506]. Proc Am Soc Clin Oncol 2010;28:15s.
-
(2010)
Proc Am Soc Clin Oncol
, vol.15 s
, pp. 28
-
-
Bokemeyer, C.1
Kohne, C.2
Rougier, P.3
-
21
-
-
70350204423
-
Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer [abstract LBA4509]
-
Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer [abstract LBA4509]. Proc Am Soc Clin Oncol 2009; 27:18s.
-
(2009)
Proc Am Soc Clin Oncol
, vol.18 s
, pp. 27
-
-
van Cutsem, E.1
Kang, Y.2
Chung, H.3
-
22
-
-
49149109102
-
Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract LBA4011]
-
Punt CJ, Tol J, Rodenburg J et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract LBA4011]. Proc Am Soc Clin Oncol 2008;26:1008s.
-
(2008)
Proc Am Soc Clin Oncol
, vol.1008 s
, pp. 26
-
-
Punt, C.J.1
Tol, J.2
Rodenburg, J.3
-
23
-
-
80052196969
-
-
Presented in part at the World Congress on Gastrointestinal Cancer
-
Presented in part at the World Congress on Gastrointestinal Cancer, Barcelona, June 25-28, 2008.
-
(2008)
Barcelona, June
, pp. 25-28
-
-
-
24
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359: 1757-1765.
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
|